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Introduction: Liquid biopsies allowing for individualized risk stratification of cancer
patients have become of high significance in individualized cancer diagnostics and
treatment. The detection of circulating tumor cells (CTC) has proven to be highly
relevant in risk prediction, e.g., in colorectal cancer (CRC) patients. In this study, we
investigate the clinical relevance of longitudinal CTC detection over a course of follow-up
after surgical resection of the tumor and correlate these findings with clinico-pathological
characteristics.
Methods: In total, 49 patients with histologically proven colorectal carcinoma were
recruited for this prospective study. Blood samples were analyzed for CTC presence by
two methods: first by marker-dependent immunofluorescence staining combined with
automated microscopy with the NYONE® cell imager and additionally, indirectly, by semi-
quantitative Cytokeratin-20 (CK20) RT-qPCR. CTC quantification data were compared
and correlated with the clinico-pathological parameters.
Results: Detection of CTC over a post-operative time course was feasible with both
applied methods. In patients who were pre-operatively negative for CTCs with the
NYONE® method or below the cut-off for relative CK20 mRNA expression after analysis
by PCR, a statistically significant rise in the immediate post-operative CTC detection could
be demonstrated. Further, in the cohort analyzed by PCR, we detected a lower CTC load
in patients who were adjuvantly treated with chemotherapy compared to patients in the
follow-up subgroup. This finding was contrary to the same patient subset analyzed with
the NYONE® for CTC detection.
Conclusion: Our study investigates the occurrence of CTC in CRC patients after surgical
resection of the primary tumor and during postoperative follow-up. The resection of theJune 2021 | Volume 11 | Article 6468851
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Frontiers in Oncology | www.frontiersin.orgtumor has an impact on the CTC quantity and the longitudinal CTC analysis supports the
significance of CTC as a prognostic biomarker. Future investigations with an even more
extended follow-up period and larger patient cohorts will have to validate our results and
may help to define an optimal longitudinal sampling scheme for liquid biopsies in the post-
operative monitoring of cancer patients to enable tailored therapy concepts for precision
medicine.Keywords: circulating tumor cells, colorectal cancer, NYONE® cell imager, CK20 RT-qPCR, longitudinal follow-up,
liquid biopsiesINTRODUCTION
Despite tremendous efforts in the diagnosis and treatment of
colorectal cancer (CRC), it still represents one of the most
common causes of cancer-related deaths in Western countries
(1). The fact that a proportion of patients is diagnosed with a
localized tumor that can be resected in sano (R0) but later
develop a tumor recurrence or distant metastases underlines
the need for valid prognostic and predictive biomarkers that help
to identify high-risk patients. Profound criteria for the
stratification of patients at risk who might benefit from an
adjuvant treatment have been developed (2, 3), though these
almost all rely on histopathological parameters amongst very few
other mutational characteristics of the primary tumor.
Consequentially, the concept of individualized diagnostics
and therapeutic options has yielded major attention in recent
years (4, 5), and biomarkers for either early detection of cancer or
proof of minimal residual disease have been identified (6). As a
potential tool, circulating tumor cells (CTC) have been identified
and their suitability to serve as an additional instrument in risk
stratification has been demonstrated manifold (7). These CTC
are shed into the peripheral bloodstream not only from the
primary but also from metastatic tumor sites and are linked to
progressive disease and metastatic formation. In most cases of
CRC patients with local disease, tumor resection is considered as
a curative approach. The impact of surgery on the CTC count in
the bloodstream has been already described, with generally a
steep increase in CTC numbers shortly after surgical resection,
but also a rapid normalization and often decrease in cell numbers
within a short period of time (8). Though, studies on the
enumeration of CTC in the long-term longitudinal follow-up
of patients with solid tumors after surgery are rare.
CTC are extremely rare in the bloodstream and their valid
detection and enumeration amongst multifarious numbers of
leukocytes pose a major challenge. Up to date, various
enrichment and detection techniques are available (9, 10).
Categorically, CTC can be directly detected and enumerated by
the means of cytological immunological staining, or indirectly
detected by molecular approaches using PCR. The cytological
approach for CTC enumeration is mostly marker-dependent,
though many techniques employ only single antibodies for
visualization of CTC. In this context, the most commonly used
target antigens are EpCAM or several cytokeratins, which are
highly specific to CTC of epithelial tumors. For the molecular
detection of CTC, we previously reported on an RT-qPCR against2
cytokeratin 20 (CK20), which was already established to determine
the prognostic value of the CTC load at the time point of surgery
in respectable CRC patients (11, 12). By the introduction of a cut-
off value allowing a relative CTC quantification, the negative
prognostic significance of the amount of CK20-positive CTC in
CRC patients could clearly be demonstrated (13).
In order to further extend these findings and to validate our CTC
detection approach, this study aimed at a proof-of-principle study
for a longitudinal follow-up of CRC patients after surgical resection
with a series of set timepoints for blood draw. Furthermore, both a
novel immunofluorescence-based and a molecular detection
approach for enumeration and detection of CTC was employed
and the results of both methods were compared. For both detection
methods, peripheral blood mononuclear cells (PBMC) were
enriched by density gradient centrifugation (Ficoll® or CPT
Vacutainer) and then applied in either analysis For enumeration
by the semi-automated cell-imager (NYONE®, SYNENTEC,
Elmshorn, Germany) CTC were immunofluorescently (IF) stained
utilizing a set of antibodies against highly specific antigens of CTC
in CRC patients, namely, anti-EpCAM, anti-EGFR, anti-pan-
Cytokeratin(CK), and anti-Her2, as established in an earlier study
(14). Additionally, an established CK20 RT-qPCR assay was applied
for relative CTC quantification, as described elsewhere (13). The
obtained data were then correlated to clinical characteristics and
follow-up records, e.g., local recurrence, adjuvant treatment. Special
emphasis was laid on the longitudinal postoperative CTC detection
since individual therapeutic decisions are frequently made based on
the histopathological characterization of the tumor at the time of
primary surgery.MATERIALS AND METHODS
Patient Recruitment and Serial Sampling
In total, 49 patients with a histologically verified CRC were
enrolled in this prospective study in the years 2017 and 2018. All
patients were operated on at the Department of General,
Visceral, Thoracic, Transplantation and Paediatric Surgery of
the University Hospital Schleswig-Holstein (UKSH), Campus
Kiel. In case staging diagnostics of a rectal carcinoma revealed a
locally progressed tumor burden with either T3/T4 and/or N+
according to the TNM classification (TNM Classification of
Malignant Tumors eighth edition), patients were admitted to a
neoadjuvant radio-chemotherapy (RCTX). Patients, who were
staged UICC (Union internationale contre le cancer) III or IVJune 2021 | Volume 11 | Article 646885
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admitted to either adjuvant or palliative chemotherapy (CTX)
post-operatively. All decisions were made according to the
present guidelines (German S3-Guideline Colorectal
Carcinoma, Version 2.1 – January 2019 AWMF-Registration
Number: 021/007OL) and the general patients´ constitution in
terms of morbidity and endorsement. All patients gave written
informed consent to participate in this study. The study was
approved by the local ethics committee of the UKSH Campus
Kiel and the Medical Faculty, University of Kiel (#A110/99).
Classification of the pathological tumor stage was handled by the
Department of Pathology, UKSH Campus Kiel, according to the
TNM-classification. Clinical data were obtained from the clinical
research database of the oncological biobank of the
Comprehensive Cancer Center Kiel (BMB-CCC) and data was
verified by re-examination of original patient records.
Blood samples from the following time points were analyzed for
the presence of CTC: Pre-operatively (t0) and the primary endpoint
of the study was reached if a patient reached the last blood draw at
12 months post-operatively (t5). For this, each patient received an
individualized follow-up regimen for a visit and blood sample
drawing at set time points after the surgical procedure: one
month (t1), three months (t2), 6 months (t3), 9 months (t4), andFrontiers in Oncology | www.frontiersin.org 312 months (t5) (Figure 1A). The peripheral blood samples were
either taken shortly prior to surgery (t0) from a central venous line
or obtained by puncture of the median cubital vein for the blood
samples collected at the follow-up time points (t1-t5).
For this study, two different approaches for CTC detection
were applied. For the immunofluorescence detection by
NYONE®, approximately 8 ml of blood were collected into a
Sodium Citrate-Monovette® (Sarstedt, Nümbrecht, Germany).
For CTC detection by PCR, approximately 20 ml of blood were
drawn into lithium heparin-Monovettes® (Sarstedt). All samples
were further processed within 2 hours after blood draw.
Sample Analysis With the Semi-Automated
Microscope—NYONE®
The establishment and procedure of CTC enumeration by semi-
automated microscopic detection with the cell imager NYONE®
(SYNENTEC, Elmshorn, Germany) has been described
previously (14). Briefly, the mononuclear cell (MNC) fraction
was isolated by Ficoll-cushion centrifugation and resuspended in
a fixation buffer (#14190-094, Biolegend, San Diego, CA, USA),
incubated for 15 minutes at room temperature (RT), after which
the samples were stored at 4°C for up to four days until
further analysis.A
B C
FIGURE 1 | Study outline and synopsis of the employed techniques for CTC detection. (A) Blood samples were collected repeatedly over a course of 12 months
post-operatively. The first blood sample of each recruited patient was drawn immediately pre-operatively t0. Over the study period, five more samples were collected
at set follow-up visits of each patient at 4 weeks (t1), 3 months (t2), 6 months (t3), 9 months (t4), and 12 months (t5). (B) NYONE® – After CTC enrichment by Ficoll
centrifugation via CPT tubes, PBMC were fixed, permeabilized, and stained with anti-CD45-Alexa488 (green to detect leukocytes), anti-EpCAM, anti-EGFR, anti-
Her2, and anti-pan-CK antibodies (all Alexa647-coupled, red to detect epithelial cells) and DAPI (blue) for nuclei staining. The enumeration process of CTC was
carried out by the cell imager NYONE®. After image analysis, CTC (DAPI positive, negative for Alexa488, and positive for Alexa647) were encircled allowing
cytological assessment. (C) Semi-quantitative RT-qPCR against CK20 –After Ficoll centrifugation of the blood plasma samples, the enriched fraction of PBMC was
isolated and cDNA was obtained after RNA preparation. Then, a TaqMan gene expression assay [KRT20 (CK20)] and TBP as a house-keeping gene were used.June 2021 | Volume 11 | Article 646885
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(#421002, Biolegend) for 5 minutes at RT and centrifuged at
330xg for 10 minutes. Afterward, cells were incubated with an
Fc-blocking buffer (#422301/2, Biolegend) for 15 minutes. Then,
cells were incubated for 30 minutes with the following
antibodies: anti-CD45-AF488 (#304017; Biolegend), anti-
EpCAM-AF647 (#324212; Biolegend), anti-pan-CK-AF647
(#628604; Biolegend), anti-EGFR-AF647 (#sc-120 AF647;
SantaCruz, Dallas, TX, USA), and anti-Her2-AF647 (#3244412;
Biolegend). Finally, a buffer containing DAPI (1:10,000)
(#422801; Biolegend) was added to the cells.
Subsequently, 200 µl of the stained cell suspension was
transferred into each a well of two 96-well plates (Sarstedt),
which was centrifuged at 330xg for 10 minutes, and afterward
placed in the NYONE® cell imager.
For analysis, the plates were scanned only for the detection of
Alexa647 fluorescence (Ex 632/22, Em 685/40) as only CTC
should be positive in this setting, which was detected by the
respective antibody cocktail against epithelial markers EpCAM,
pan-cytokeratin, EGFR, HER2. SYNENTEC’s proprietary YT®-
Software automatically analyzed the images already during
scanning and detected positive events (Figure 1B). The image
processing settings for this analysis were determined previously
using blood samples from healthy donors spiked with HT29
tumor cells (14). Each event was then automatically further
analyzed in depth by creating a region of interest (ROI) around
it. This ROI was scanned in four channels (DAPI: Ex 377/50 Em
452/45, Alexa488: Ex 475/28 Em 530/43, Alexa-647: Ex 632/22 Em
685/40, brightfield: Ex brightfield Em blue). YT®-Software then
automatically detected the cells´ nuclei (DAPI, blue fluorescence)
and analyzed whether a virtual cytoplasm surrounding the nuclei
was fluorescing green (CD45) or red (EpCAM, pan-CK, EGFR,
Her2). These events were finally presented separately by the
software and the investigator was able to examine the
morphology of the potential CTC (Figure 1B).Sample Analysis by Molecular mRNA
Detection: Semi-Quantitative CK20 RT-qPCR
The application of a semi-quantitative CK20 RT-qPCR for CTC
detection (Figure 1C) in CRC patients has been previously
established in our work group (13). Briefly, blood samples were
processed by ficoll-centrifugation to isolate the MNC fraction.
Then, RNA was isolated with RNAPure® reagent (VWR Peqlab,
Darmstadt, Germany) and cDNA was obtained by reverse
transcription of 3 mg total RNA (Maxima First Strand cDNA
Synthesis Kit, Thermo Fisher Scientific, Darmstadt, Germany).
The qPCRs were run in a total volume of 20 ml per well of a
96-well plate (Sarstedt) using the TaqMan gene expression assays
for CK20 (KRT20, Hs00966063_m1) and for the housekeeping
gene TBP (TATA-box binding protein), Hs00427620_m1, as a
reference in combination with the TaqMan Fast Advanced
Master Mix on a StepOne Plus realtime PCR System (all
ThermoFisher Scientific). All samples were run in triplicate.
Relative gene expression was calculated as arbitrary expression
units [EU] by a simplified DCt method normalizing the CK20
expression against the reference gene TBP expression.Frontiers in Oncology | www.frontiersin.org 4Statistical Analysis
All reported P-values are two-sided and were regarded statistically
significant at P < 0.05. When a Gaussian distribution of the data
was assumed, the parametric data were analyzed by either a
repeated measure or ordinary one-way-ANOVA test. Non-
parametric data were analyzed by a Mann-Whitney U-test.
Statistical calculation and testing were performed with
GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA).RESULTS
Patients Demographics
A synopsis of all patient data relating to the entire cohort but also
the subgroups in terms of detection method is given in Table 1.
In total, blood samples from 49 patients were included in this
prospective study (Figure 1A). A total of 30 male and 19 female
patients were enrolled and the median age at the time of
operation and first blood sample collection was 67 years
(range: 48–89 years). In total, 32 patients were diagnosed with
colon carcinoma and 17 patients with rectal carcinoma. Amongst
the colon carcinoma subset, an equal composition between left-
and right-sided carcinoma (both 16 cases) was noted. The study
cohort was further stratified by a clinico-pathological staging
according to the UICC stages I-IV, with the most patients
diagnosed with stage III (38.8%). In total, 10 patients (all rectal
carcinoma) were treated by neoadjuvant radio-chemotherapy,
and 18 patients received adjuvant chemotherapy.TABLE 1 | Patient demographics and clinical characteristics of the entire study
population and further breakdown according to the utilized detection modes.
Total N (%) NYONE N (%) CK20 N (%)
49 (100) 44 (100) 47 (100)
Gender
Male 30 (61.2) 26 (59.1) 29 (61.7)
Female 19 (38.8) 18 (40.9) 18 (38.8)
Age
Median (range) 67 (45-89) 66 (45-89) 67 (45-89)
<65 21 (42.9) 18 (40.9) 21 (44.7)
≥65 28 (57.1) 26 (59.1) 26 (55.3)
Tumor site
Colon 32 (65.3) 32 (72.7) 30 (63.8)
Right 16 (50.0) 16 (50.0) 15 (50.0)
Left 16 (50.0) 16 (50.0) 15 (50.0)
Rectum 17 (34.7) 12 (27.3) 17 (36.2)
UICC stage
I 14 (28.6) 12 (27.3) 14 (29.8)
II 9 (18.4) 9 (20.5) 8 (17.0)
III 19 (38.8) 18 (40.9) 18 (38.3)
IV 7 (14.3) 5 (11.4) 7 (14.9)
Neoadj. treatment
Yes 10 (58.8) 6 (50.0) 10 (58.8)
No 7 (41.2) 6 (50.0) 7 (41.2)
Adjuvant treatment
Yes 18 (36.7) 14 (31.8) 17 (36.2)
No 31 (63.3) 30 (68.2) 30 (63.8)June 2021 | Volume 11 | AThe subset of patients who received neoadjuvant treatment solely comprised of patients
with rectal carcinoma. UICC, Union internationale contre le cancer.rticle 646885
Hendricks et al. Longitudinal CTC AnalysisAltogether, 44 and 47 patients were enrolled for CTC analysis
by the cytological semi-automated microscopy (NYONE®,
Figure 1B) and the indirect molecular approach by CK20 RT-
qPCR (Figure 1C), respectively. Generally, the distribution of the
two subsets of patients according to the demographical and
clinical parameters was assimilable. The median age of patients
within the NYONE® subgroup was 66 years (range: 45–89 years)
and within the PCR group 67 years (range: 45–89 years) at the
time of blood draw. In both groups, the majority of patients were
male (59.1% – NYONE® and 61.7% – PCR) and were diagnosed
with a colon carcinoma (72.7% – NYONE® and 63.8% – PCR).
Again, most of the patients were diagnosed with locally advanced
tumor burden and staged UICC III (40.9% – NYONE® and
38.3% PCR).
Longitudinal Analysis of CTC Count
by IF and the NYONE® Cell-Imager
Altogether, we were able to enroll 44 patients for the longitudinal
follow-up. During the time of the study period, the number of
patient re-visits declined (Figure 1A).
In general, positivity rates during the collection time-course of
CTC by the NYONE® technique were low and comparable at the
first (pre-operative, t0) time points (Table 2), ranging between a
mean CTC count of 0.89 and 1.5. At t5, a considerable increase of
the mean CTC count could be observed (mean 4.25 CTC; SD:
10.01). However, this might be explained by one patient´s
exceedingly high CTC count of 29 IF-positive cells.
Surgical resection of the tumor did not seem to have an effect
on the frequency of CTC in the peripheral blood of the patients as
the mean count of CTC was 0.89 CTC (range: 0–7 CTC; SD: 1.57)
at t0 (prior to surgery) and 1.18 CTC (range: 0–4 CTC; SD: 1.33) at
t1 (p not significant). Furthermore, analyzing the following blood
samples over the time course, the CTC count of the overall study
population did not show any significant alterations from the initial
CTC prevalence (all p not significant) (Table 2 and Figure 2A).
Stratifying the study population by means of CTC positivity
(n=16 patients) vs. negativity (n=28 patients) at t0, a statistically
significant increase in the CTC count at t1 was monitored in theFrontiers in Oncology | www.frontiersin.org 5subgroup without any pre-operative signs of CTC (mean: 0.00;
SD: 0.00 at t0 and mean: 0.93; SD: 1.22 at t1; p=0.023). In all
other measurements at later time points of the study, no
significant differences compared to the baseline at t0 were
observed in this subgroup (all p not significant) (Figure 2B).
In contrast, in patients who initially had shown evidence of CTC
in the peripheral blood, a general decrease in CTC by trend could
be monitored (Figure 2C).
Next, we further stratified the cohort by adjuvant
chemotherapeutic treatment and analyzed patients who
received treatment (CTX+) in comparison to patients who
were solely admitted to follow-up care (CTX-). We analyzed
the patients´ CTC counts accordingly and compared the mean
cell counts of CTC at each time point individually. Surprisingly,
CTX+ patients showed higher CTC counts almost throughout
the entire study period with a statistically significant higher CTC
amount at t5 (CTX+: mean 7.75 cells, SD 14.17 vs. CTX-: mean
0.75 cells, SD 0.5; p=0.015) (Table 2 and Figure 2D).
We additionally analyzed the development of the cohort
during the observation period based on the amount of CTC.
Subgroups were defined by the absence of CTC (0 cells per
patient sample), intermediate frequency (1–2 cells per patient
sample), and high CTC rates (≥3 cells per patient sample). The
definition of high CTC frequency as ≥3 cells was based on
different studies which proposed this as a clinically significant
cut-off determined by the CellSearch® system (15). Interestingly,
while the percentage of patients with no cells in the blood
declined during the time period of the study, a highly
significant increase in patients with both intermediate (1–2
CTC) and high prevalence of CTC (≥3 CTC) was monitored
for the duration of the study (p=0.002) (Figure 2E). In detail, at
t0 approximately 63.3% of the patients were CTC negative while
at t5 the percentage declined to 25.0%.
Longitudinal Analysis of the Relative CTC
Load by CK20 RT-qPCR
In total, 47 patients were recruited in this study arm. Table 1
gives an overview of the clinical and pathological data of theTABLE 2 | CTC quantity partitioned for each technique of CTC detection and outlined for each follow-up timepoint with association of the impact of adjuvant
chemotherapy on the CTC quantity over the study period.
t0 p t1 p t2 p t3 p t4 p t5 p
NyOne
CTC positive patients: fraction (%) 16/44 (36.4) 12/22 (54.5) 12/22 (54.5) 9/20 (45.0) 7/12 (58.3) 6/8 (75.0)
CTC count per patient: mean (SD) 0.89 (1.57) 1.18 (1.33) 1.50 (2.61) 1.00 (1.69) 1.33 (1.67) 4.25 (10.01)
CTC count according to adjuvant chemotherapy
CTX+: mean (SD) 1.50 (2.28) ns 2.60 (1.34) ns 2.25 (3.28) ns 0.86 (0.90) ns 0.83 (0.98) ns 7.75 (14.17) 0.015
CTX-: mean (SD) 0.60 (1.04) 0.76 (1.03) 1.07 (2.16) 1.08 (2.02) 1.83 (2.14) 0.75 (0.50)
CK20 RT-qPCR
CTC positive patients: fraction (%) 33/41 (80.5) 19/22 (86.4) 17/22 (77.3) 16/20 (80.0) 7/12 (58.3) 8/8 (100.0)
CTC count per patient: mean (SD) 3.11 (3.81) 3.55 (6.17) 3.08 (3.19) 2.41 (1.62) 1.61 (1.95) 4.16 (5.66)
Patients ≥ cut-off: fraction (%) 15/41 (36.6) 8/22 (36.4) 11/22 (50.0) 10/20 (50.0) 2/12 (16.7) 3/8 (37.5)
CTC count according to adjuvant chemotherapy
CTX+: mean (SD) 2.43 (2.42) ns 2.00 (1.85) ns 3.21 (3.98) ns 1.74 (1.45) ns 1.21 (1.49) ns 1.86 (0.55) ns
CTX-: mean (SD) 3.40 (4.26) 4.14 (7.13) 3.00 (2.81) 2.76 (1.64) 2.01 (2.41) 6.45 (7.77)June 2021 | Volume 11 | Article 6All p values in bold are regarded as statistically significant. UICC, Union internationale contre le cancer; SD, standard deviation; CTC, Circulating tumor cells; CTX, chemotherapy;
ns, not significant.46885
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operation and further samples that allowed for longitudinal
CTC analysis were available from 41 patients.
In terms of tumor stages, the present patient cohort is
representative, and the sensitivity rate of our applied CK20
RT-qPCR (80.42% positive for CTC, Table 2) is comparable to
our previously reported data (13).
In line with the findings obtained with the NYONE® cell
imager, no statistically significant short-term effect on the CTC/
CK20-positivity load by the surgical procedure could be observed
(mean: 3.11 [EU], SD: 3.81 at t0, and mean: 3.55 [EU], SD: 6.17 at
t1; p not significant). Like the cytological analysis with the
NYONE® cell-imager, the RT-qPCR analysis did also not reveal
any significant alteration of the relative CTC/CK20-positivity
throughout the study period compared to the pre-operative
CTC signal at t0 (all p not significant) (Table 2 and Figure 3A).
Next, we further stratified patients by applying a clinically and
prognostically relevant cut-off for relative CTC positivity by
CK20 RT-qPCR, which was established in a previous study
(13). Patients were divided into two subgroups pre-operatively
exhibiting either a high CTC positivity (≥2.77 [EU]; CTC-high)
or a low CTC positivity (<2.77 [EU]; CTC-low). Patients who
were pre-operatively (t0) in the CTC-low group, post-operatively
(t1) showed a statistically significant increase in CTC numbersFrontiers in Oncology | www.frontiersin.org 6measured by CK20 RT-qPCR (mean: 1.17 [EU], SD: 0.85 at t0 vs.
4.36 [EU], SD: 7.94 at t1; p=0.047) (Figures 3B, D) which then
declined again until t4 (mean: 0.78 [EU], SD: 0.99). Interestingly,
a statistically significant increase in the relative CTC/CK20-
positivity could be monitored from 9 to 12 months after
surgery (t4 to t5; mean: 0.78 EU, SD: 0.99 at t4 vs. mean: 2.44
EU, SD: 0.77 at t5; p=0.018).
In contrast, in patients with a pre-operative high CTC-
positivity, the surgical procedure and hence tumor burden
reduction significantly reduced the CTC load during the first
month (mean: 6.49 EU, SD: 4.56 at t0 vs. 2.68 EU, SD: 1.51 at t1;
p<0.001). However, analyses at later time points throughout the
study then revealed a slight increase of CTC compared to the
post-operative CTC load at t1 (Figures 3C, E).
Interestingly, comparing the data obtained at t1 of both patient
subsets, no difference emerged in the relative quantity of CTC
between the groups (mean: 2.68 [EU], SD: 1.51 at t1 CTC high and
mean: 4.36 [EU], SD: 7.94 at t1 CTC low; p=ns). Patients with pre-
operative high CTC counts dropped post-operatively to a
comparable level of patients with pre-operative low CTC counts
who exhibited a post-operative increase in relative CTC loads.
Next, we subdivided the patients examined by CK20 RT-
qPCR according to their status of adjuvant chemotherapy




FIGURE 2 | Longitudinal analysis of blood samples of 44 CRC patients for the incidence and enumeration of CTC by a semi-automated microscopical approach
with NYONE®. (A) In the study cohort as a whole, no statistically significant deviations in terms of an in- or decrease of the CTC count compared to t0 could be
observed. The bar represents the mean count of CTC. (B, C) The individual patient with its longitudinal CTC quantification data is displayed by each line (each color
represents one patient). (B) All patients that pre-operatively (t0) had no detectable CTC were analyzed in this subset. At t1, there was a statistically significant
(p=0.023) increase in the CTC quantity. Throughout the further visits, no significant deviation from the initial CTC quantity (t0) was observed. (C) All patients with
detectable CTC at t0 were sub-grouped for this analysis. There was no statistical significance for deviations over the study period from the initial CTC count.
(D) Patients were stratified and subdivided according to their necessity of adjuvant chemotherapeutic treatment (CTX+). Patients that did not require adjuvant
treatment were grouped in the follow-up subset (CTX-). (E) Patients were stratified and grouped according to the patients´ individual quantity of CTC: No CTC, 1-2
CTC (intermediate), ≥3 CTC (high). Analyzing the data as fractions of a whole, throughout the study a significant increase of patients with intermediate or high CTC
counts was monitored.June 2021 | Volume 11 | Article 646885
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analysis, CTX seemed to have an effect on the CTC
enumeration. Patients in the CTX+ cohort showed lower
relative CTC counts by trend at almost all re-visits. Only at t2
was there a slightly higher CTC count in patients of the CTX-
subgroup (CTX+: mean 3.21 [EU], SD 3.98 vs. CTX-: mean 3.00
[EU], SD 2.81; p=ns) (Table 2 and Figure 3F)
Evaluation of Individual Longitudinal
Patient Courses
After having analyzed the overall cohort, we next focused on
patients´ individual CTC courses detected by the two
enumeration methods and linking the obtained results to the
clinical follow-up data.
Figure 4A exemplarily displays the context and interplay of
CTC enumeration and adjuvant treatment after surgery. This
patient was diagnosed with an adenocarcinoma of the
descending colon, but with locally progressed tumor burden
and nodal positive stage III disease. In line with the guidelines
(German S3-Guideline Colorectal Carcinoma, Version 2.1 –
January 2019 AWMF-Registration Number: 021/007OL) the
patient was admitted to adjuvant chemotherapy after surgical
resection. Fitting to the advanced tumor burden, the patient
showed exceptionally high numbers of CTC pre-operatively (t0)
(NYONE®: 7 cells, PCR: 7.44 [EU]) in comparison to the general
average of the cohort. Around 1 month (t1) after surgery and
shortly before initiation of chemotherapy, the CTC count hadFrontiers in Oncology | www.frontiersin.org 7dropped significantly (NYONE®: 2 cells, PCR: 2.77 [EU]) and
remained below the cut-off values of both detection methods
during the entire course of adjuvant chemotherapy (t1 up to t3)
and the end of the observation period (t5). However, even though
CTC enumeration from t3 until t5 was below the cut-off value, the
PCR-based approach revealed a slight increase in the CTC
enumeration starting at t4, at which the cytological approach
further indicated a decline in the CTC load. Tumor markers CEA
and CA19.9 weremonitored at t0 and were not elevated at that time.
Follow-up diagnostics were performed within the investigation
period and did not show any signs of macroscopical tumor
relapse. Since the patient dropped out of the study after t5, we
could not further elaborate whether the CTC increase determined
indirectly by CK20 RT-qPCR was indicative of a reactivation of a
minimal residual disease (MRD) and clinical relapse.
Figure 4B exemplarily displays the disease course of a patient
diagnosed with a stage II adenocarcinoma of the descending
colon and provides an example of the potential of CTC as
biomarkers for add-on recurrence diagnostics. According to
the general guidelines (German S3-Guideline Colorectal
Carcinoma, Version 2.1 – January 2019 AWMF-Registration
Number: 021/007OL), adjuvant chemotherapy was not given,
and the patient was only admitted to oncological follow-up. Pre-
operatively (t0), no CTC could be detected with the NYONE®
cell imager and the relative enumeration by CK20 RT-qPCR also
revealed a measurement below the cut-off value. At t2 (3 months
later), CTC detection by both the NYONE® and PCR was stillA B
D E F
C
FIGURE 3 | Longitudinal analysis of blood samples of 47 CRC patients for the incidence and relative enumeration of CTC by a semi-quantitative CK20 RT-qPCR.
Results are expressed by expression units [EU]. The bar represents the mean relative CTC count expressed by [EU]. (A) The entire study cohort is analyzed, and no
statistically significant deviations of the relative CTC count compared to t0 were monitored. (B–E) The previously reported clinically significant cut-off value for CTC
detection by CK20 PCR in CRC patients (13) was applied and the cohort stratified for further analysis. (B, D) In patients, who were below the cut-off at t0, a
significant increase in CTC at t1 was monitored (p=0.047). No further differences were monitored at later visits compared to t0. Each color represents an individual
patient. (C, E) For patients who were above the cut-off at t0, a significant decrease in the relative CTC quantity was recorded (p<0.001). No further significant
deviations were monitored at later visits. (F) Patients were stratified and subdivided according to their necessity of adjuvant chemotherapeutic treatment (CTX+).
Patients that did not require adjuvant treatment were grouped in the follow-up subset (CTX-). *p≤0.05; ***p≤0.001.June 2021 | Volume 11 | Article 646885
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decrease of the CTC count (1.46 [EU] at t0 and 1.10 [EU] at
t2). At t3 (6 months later), a relevant increase of the relative CTC
enumeration above the cut-off value could be monitored by
CK20 RT-qPCR (3.09 [EU]), while the NYONE® analysis still
did not reveal any CTC positivity. At t4 (9 months after surgery),
a significant increase in the CTC count could also be detected by
the microscopical enumeration approach (0 cells at t0-t3 and 4
cells at t4). The last measurement at t5 (12 months after surgery)
revealed a continuous increase in the relative quantification of
CTC by CK20 RT-qPCR (3.50 [EU]), but surprisingly a declining
cytological detection by the NYONE® (4 cells at t4 and 1 cell at
t5). Interestingly, 13 months after initial surgery, a local
recurrence of the primary adenocarcinoma was detected.
Important to note that the tumor markers CEA and CA19.9
were below the cut-off levels at all times. In summary, these
findings suggest that we were able to monitor a significant
increase in CTC by both techniques being indicative of a
reactivation of an MRD prior to its detection by the imaging
diagnostics conducted according to the standard guidelines of
follow-up (German S3-Guideline Colorectal Carcinoma, Version
2.1 – January 2019 AWMF-Registration Number: 021/007OL).DISCUSSION
The benefit of CTC diagnostics as a biomarker for assessing the
disease prognosis in cancer patients is evident (6, 9). However, the
majority of studies firstly focus on patients with systemic stage IV
disease and, secondly, conclude the patients’ prognosis by CTC-
analysis from a single pre- or post-operative blood sample only.
Accordingly, CTC numbers or CTC associated parameters were
determined only once and correlated with the clinical follow-up
(16–21). Only very few studies have analyzed the prognostic potential
of longitudinal CTC quantification over a period of time (22, 23).
In this prospective pilot study, we longitudinally monitored a
cohort of CRC patients of miscellaneous tumor stages, whoFrontiers in Oncology | www.frontiersin.org 8underwent surgical resection of the tumor and postoperatively
were either admitted to oncological follow-up or adjuvant
chemotherapy treatment. All patients enrolled were recontacted
for serial blood samples, partially on the occasion of routine follow-
up examination over a course of 12 months post-operatively. CTC
enumeration was carried out by two differing techniques,
(i) cytologically, by IF staining and microscopical detection by the
semi-automated cell imager (NYONE®), and (ii) molecularly, by a
semi-quantitative RT-qPCR detecting CK20 mRNA as an epithelial
cell marker. CTC enumeration data obtained by either method was
correlated with clinical characteristics and follow-up data.
Firstly, contrary to our expectations, surgery did not have any
statistically significant effect on the quantity of CTC detected by
the cytological approach utilizing the cell imager NYONE®
regarding the overall complied cohort of our study population.
Generally, and described by Galizia et al. (24), one could expect
the resection of the tumor to have a significant negative impact
on the incidence of CTC postoperatively in the overall cohort.
Despite this, we were able to demonstrate a significant short-
term increase in CTC quantity post-operatively but only in
patients who were pre-operatively negative for CTC in the
cytological method or below the cut-off in the PCR-based
analysis. During the surgical procedure and mechanical
manipulation of the tumor, an excess of CTC may be released
into the bloodstream (25–27). Owing to a short half-life of CTC,
their numbers are significantly reduced but still elevated 3 months
after surgery compared to the preoperative status. Interestingly, in
patients who pre-operatively showed evidence for CTC in the
NYONE® or were above the cut-off for the CK20 RT-qPCR
method, CTC levels post-operatively dropped significantly.
Concluding, the removal and physical manipulation of the
tumor in this subset of patients did surprisingly lead to a
significant decrease in CTC numbers in the short term. In a
large single-center study comprising 403 patients with breast
cancer, van Dalum et al. analyzed CTC with the CellSearch®
system over a long follow-up period (median 5.7 years). In their
study, they did not observe any relevant impact of the surgicalA B
FIGURE 4 | Evaluation of CTC load during individual longitudinal patient courses. CTC were enumerated by two altering methods: cytologically after IF-staining by
detection with the NYONE® (blue line) and molecularly by analysis of CK20-gene expression by RT-qPCR (red line). The asterisk indicates the time point of diagnosis
of the local recurrence of carcinoma. The black dotted line indicates the interval of chemotherapy. The orange line represents the clinically significant cut-off value of
CTC detected by CK20 RT-qPCR. (A) CRC patient with stage III carcinoma of the descending colon. After the operation, the CTC load dropped markedly and under
the adjuvant therapy, no significant rise in CTC was observed. (B) CRC patient with stage II carcinoma of the descending colon. A total of 24 weeks after the
operation, a clear rise of CTC in both detection methods was monitored, with the PCR-based approach being even earlier Clinically no significant follow-up event
was recorded. Thirteen months after t0 a local recurrence of the carcinoma was diagnosed.June 2021 | Volume 11 | Article 646885
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constant over the study period (28). Then again, CTC are often
thought to be directly linked to the primary tumor. Hence, once
the tumor is resected, the general opinion would be that CTC
numbers are decreasing and due to CTC clearance ultimately
disappear from peripheral blood samples. Our data suggest that
CTC remain detectable even in the mid and long-term after the
surgical procedure. Notable in this context is the exceedingly high
CTC count of 29 IF positive cells in one patient twelve months post-
operatively. Interestingly, this was a patient who was diagnosed with
a colon cancer of the descending colon with a singular hepatic
metastasis who underwent synchronous resection of the primary
tumor and the metastasis. Then, the patient received an adjuvant
chemotherapy and CTC counts remained low throughout the study
period. The blood draw at t5 was during the routine visit of
oncological follow-up. Unfortunately, the patient then dropped
out for further analysis.
Presumably, these CTC are shed into the bloodstream and are
derived from disseminated tumor cells (DTC) that rest in a
dormant-like stage in the bone marrow or lymph nodes. When
suitable triggers are active, they initiate local recurrence or
macro-metastasis.
In a xenograft mouse model and co-culture experimental set-up,
Möhrmann et al. demonstrated the importance of DTC and their
potential to act as a source for tumor relapse (29). In a study of
breast cancer patients, Meng et al. showed that in 13 of 36 patients,
where follow-up data were available, CTC were detectable up to 22
years after treatment. As they concluded slowly replicating or
dormant DTC to be the cause of this (30), it is reasonable to
assume that the origin of CTC detectable in our patients after
surgical removal of the tumor are DTC or derivatives of these.
Furthermore, our data further underscore the potential of
CTC as prognostic biomarkers in CRC, which has been already
shown in previous studies (11–13). By applying our CK20 RT-
qPCR on blood samples over the post-operative course of the
disease, we were able to detect a relative rise in CTC ahead of
clinical symptoms or positive radiological imaging in a patient
with stage II colon carcinoma who was diagnosed with local
tumor recurrence thirteen months after tumor resection
(Figure 4A). In other malignancies, for instance, in leukemia
patients, the concept of molecular minimal residual disease
(MRD) monitoring is well established (31). PCR methods for
detection of genes or genetic aberrations for MRD monitoring
have been standardized by the Europe Against Cancer (EAC)
consortium and are widely instituted (32). In terms of colorectal
cancer as a common solid tumor entity, concepts comparable to
the MRD monitoring in leukemia are still lacking. The follow-up
is mainly conducted by clinical examinations and imaging
diagnostics according to the general guidelines (German S3-
Guideline Colorectal Carcinoma, Version 2.1 – January 2019
AWMF-Registration Number: 021/007OL). In this study, we
demonstrate an example where disease monitoring by CK20
RT-qPCR based CTC detection is feasible and plausible. Even
though no clinical recommendation can be drawn based on our
data yet, attention should be given to the unambiguous case
report of the stage II colon cancer patient reported on above.Frontiers in Oncology | www.frontiersin.org 9In our study, we were able to identify patients with unusual
CTC courses. The initial blood draw, revisit and correlation of
the data with clinical follow-up characteristics of some patients
allowed for individual insights into the prognostic potential and
relevance of CTC. Again, the vast majority of studies focus on the
overall potential of CTC as a biomarker in cancer patients. Larger
patient cohorts are recruited, and the relevance of CTC
enumeration is correlated to clinical follow-up data. Though,
for further analysis of the principles of changes over time in the
CTC quantity, further in-depth analysis possibly also
investigating the biology of these individual CTC are desirable.
Future investigations on the prognostic potential of CTC in
the follow-up analysis of CRC patients should aim at a multi-
marker approach. As a widely employed and well-esteemed
technique for CTC detection, CellSearch® (Menarini Silicon
Biosystems) is up to date the only method approved by the
FDA (Food and Drug Administration) and therefore
commercially available for clinical application. Here, CTC are
enriched and enumerated by an immunological antibody-based
method, which has been described in detail elsewhere (33). The
CellSearch® technique utilizes antibodies targeting two antigens:
EpCAM and EGFR. The clinical significance had been documented
firstly by Cohen et al. in a large prospective study, though patients
enrolled were all diagnosed with stage IV disease (15). It is the
general opinion that a high tumor burden with distant metastasis
(stage IV disease) correlates with high numbers of CTC, hence the
detection of CTC by those two markers as applied by CellSearch® is
presumably more likely leading to significant numbers of CTC.
Only very few studies were conducted analyzing non-metastatic
CRC patients and the incidence of CTC by CellSearch® detection. A
possible explanation could be the concise enumeration rates of CTC
detected by CellSearch®. As presented by Thorsteinson et al. in their
study analyzing the prognostic relevance of CTC detection by
CellSearch® in non-metastatic patients, the detection rate of CTC
is poor (34), though the samples size in terms of the number of
patients recruited was quite small. Another investigation by
Gazzaniga et al., in which high-risk non-metastatic CRC patients
were enrolled, led to similar results of low CTC numbers detected
and a lack of correlation with clinical characteristics or efficacy as a
prognostic marker (35). Perchance, the sensitivity of the
CellSearch® system is limited due to only two markers being
applied, and hence the rate of undetected CTC is high.
Therefore, to overcome this potential pitfall, we intended to
establish a strategy employing a multi-marker approach
extending the utilized range of markers EpCAM and EGFR by
two further broadly established epithelial markers: pan-CK and
HER2. However, despite broadening the range of applied
markers for detection, the rate of CTC was also low in our
study. A possible explanation for this could be the process of
Epithelial-Mesenchymal-Transition (EMT). CTC that have
undergone this process may have lost or downregulated such
epithelial antigens (36, 37). Consequently, these CTC were
missed by IF staining for our markers and thus not detected.
Few studies have been published analyzing appropriate
mesenchymal marker antigens for CTC detection in CRC
patients. Yokobori et al. for example, have identified the actin-June 2021 | Volume 11 | Article 646885
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CRC patients and demonstrated its negative prognostic value in a
large patient cohort (38). In future efforts, the significance and
potential of mesenchymal antigens have to be further validated. An
approach for evading the issue of epithelial- and mesenchymal-
specific detection of CTC could be the label-free isolation and
enumeration. In general, CTC are thought to be significantly larger
(>8 µm) than leucocytes, allowing for the concept of isolation by size
of epithelial tumor cells (ISET) (39, 40). One way of conducting
CTC enumeration by ISET is the filtration of blood samples through
a porous membrane, allowing leucocytes to pass and CTC to be
effectively retained on the membrane as it has been exemplarily
demonstrated with the ScreenCell® isolation devices (ScreenCell®,
Sarcelles, France). Staining of these CTC then allows for cytological
analysis and enumeration. The feasibility and prognostic value have
been demonstrated (18, 41, 42).
In summary, our study enlightens the kinetics of CTC in CRC
patients after resection of the primary tumor and provides data
concerning the CTC quantity over a long-term follow-up. This
study not only supports the significance of CTC as a prognostic
biomarker but also provides a more in-depth longitudinal
analysis of CTC over the course of the disease. Furthermore,
these data suggest that by using CK20 RT-qPCR for CTC
detection and enumeration approach (e.g., during long-term
follow-up), a molecular MRD monitoring might be feasible in
CRC patients allowing earlier detection and therapy decision
making in relapse situations. However, future investigations with
an even more extended follow-up and larger patient cohorts will
have to validate our results and may help to define an optimal
longitudinal sampling scheme for liquid biopsies in the post-
operative monitoring of cancer patients to enable tailored
therapy concepts for precision medicine.DATA AVAILABILITY STATEMENT
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